SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Isomaki Pia)
 

Sökning: WFRF:(Isomaki Pia) > Haematological mali...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005145naa a2200517 4500
001oai:DiVA.org:uu-498975
003SwePub
008230323s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:151829042
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4989752 URI
0247 a https://doi.org/10.1136/rmdopen-2022-0027762 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1518290422 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Cordtz, Rene Lindholmu Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark4 aut
2451 0a Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors :b a Nordic cohort study
264 c 2022-12-23
264 1b BMJ Publishing Group Ltd,c 2022
338 a electronic2 rdacarrier
520 a Objectives To evaluate the risk of haematological malignancies in patients with psoriatic arthritis (PsA) overall, and in relation to treatment with tumour necrosis factor inhibitors (TNFi).Methods We identified that patients with PsA starting a first TNFi from the clinical rheumatology registers (CRR) in the five Nordic countries (n=10 621) and biologics-naive PsA patients from (1) the CRR (n=18 705) and (2) the national patient registers (NPR, n=27 286, Sweden and Denmark) from 2006 through 2019. For Sweden and Denmark, general population comparators were matched 5:1 to PsA patients on birth year, year at start of follow-up and sex. By linkage to the national cancer registers in all countries, we collected information on haematological malignancies overall, and categorised into lymphoid or myeloid types. We estimated incidence rate ratios (IRRs) with 95% CIs using modified Poisson regression for TNFi-treated versus biologics-naive PsA patients and versus the general population adjusted for age, sex, calendar period and country.Results During 59 827 person-years, 40 haematological malignancies occurred among TNFi-treated patients with PsA resulting in a pooled IRR of 0.96 (0.68-1.35) versus biologics-naive PsA from CRR and an IRR of 0.84 (0.64-1.10) versus biologics-naive PsA from NPR. The IRR of haematological malignancies in PsA overall versus general population comparators was 1.35 (1.17-1.55). The estimates were largely similar for lymphoid and myeloid malignancies.Conclusions Treatment with TNFi in patients with PsA was not associated with an increased incidence of haematological malignancies. Conversely, a moderately increased underlying risk was seen in patients with PsA compared with the general population.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
7001 a Askling, Johanu Karolinska Institutet4 aut
7001 a Delcoigne, Benedicteu Karolinska Institutet4 aut
7001 a Smedby, Karin E.u Karolinska Institutet4 aut
7001 a Baecklund, Eva,d 1956-u Uppsala universitet,Reumatologi4 aut0 (Swepub:uu)evaba786
7001 a Ballegaard, Christineu Univ Copenhagen, Bispebjerg & Frederiksberg Hosp, Parker Inst, Copenhagen, Denmark4 aut
7001 a Isomaki, Piau Tampere Univ Hosp, Ctr Rheumatol, Tampere, Finland.;Fac Med & Hlth Technol, Tampere, Finland4 aut
7001 a Aaltonen, Kalleu Minist Social Affairs & Hlth, Pharmaceut Pricing Board, ROB FIN, Helsinki, Finland4 aut
7001 a Gudbjornsson, Bjornu Univ Iceland, Landspitali Univ Hosp Iceland, Ctr Rheumatol Res, Reykjavik, Iceland.;Univ Iceland, Fac Med, Reykjavik, Iceland4 aut
7001 a Love, Thorvardur Jonu Univ Iceland, Fac Med, Reykjavik, Iceland.;Landspitali Univ Hosp Iceland, Dept Sci, Reykjavik, Iceland4 aut
7001 a Provan, Sella Aarrestadu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway4 aut
7001 a Michelsen, Brigitteu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway.;Sorlandet Hosp Kristiansand, Div Rheumatol, Kristiansand, Norway4 aut
7001 a Sexton, Josephu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway4 aut
7001 a Dreyer, Leneu Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark.;Aalborg Univ, Dept Clin Med, Aalborg, Denmark4 aut
7001 a Hellgren, Karinu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark4 org
7730 t RMD Opend : BMJ Publishing Group Ltdg 8:2q 8:2x 2056-5933
8564 u https://doi.org/10.1136/rmdopen-2022-002776y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1745681/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498975
8564 8u https://doi.org/10.1136/rmdopen-2022-002776
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:151829042

Hitta via bibliotek

  • RMD Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy